Subclinical vascular disease in patients with diabetes is associated with insulin resistance
Publication date: Available online 23 May 2019Source: Diabetes &Metabolic Syndrome: Clinical Research &ReviewsAuthor(s): María M. Adeva-Andany, Raquel Funcasta-Calderón, Carlos Fernández-Fernández, Eva Ameneiros-Rodríguez, Alberto Domínguez-MonteroAbstractPatients with diabetes experience increased cardiovascular risk that is not fully explained by deficient glycemic control or traditional cardiovascular risk factors such as smoking and hypercholesterolemia. Asymptomatic patients with diabetes show structural and functional vascular damage that includes impaired vasodilation, arterial stiffness, increased intima-media thickness and calcification of the arterial wall. Subclinical vascular injury associated with diabetes predicts subsequent manifestations of cardiovascular disease, such as ischemic heart disease, peripheral artery disease and stroke. Noninvasive detection of subclinical vascular disease is commonly used to estimate cardiovascular risk associated to diabetes. Longitudinal studies in normotensive subjects show that arterial stiffness at baseline is associated with a greater risk for future hypertension independently of established risk factors. In patients with type 2 diabetes, vascular disease begins to develop during the latent phase of insulin resistance, long before the clinical diagnosis of diabetes. In contrast, patients with type 1 diabetes do not manifest vascular injury when they are first diagnosed due t...
CONCLUSIONS: It appears that cycling has a positive effect on walking speed, walking ability and balance. Functional electrical stimulation combined with cycling has positive effects on balance beyond cycling alone. PMID: 31227660 [PubMed - in process]
CONCLUSIONS: Neurological patients showed a misperception of the verticality, estimated using the SVV. The neurological pathology that most alters the SVV is stroke. PMID: 31227659 [PubMed - in process]
CONCLUSIONS: Multiple sessions of STT practice can improve paretic arm function and decrease TCI bilaterally, with no additional benefit of prior cTBS. Our results suggest that improvement in STT practice following M1c cTBS scaled with change in paretic arm function in some individuals. Our results highlight the need for a better understanding of the mechanisms of cTBS to effectively identify who may benefit from this form of brain stimulation. PMID: 31227676 [PubMed - in process]
This study aimed to assess the time course of hemodynamic patterns of cortical sensorimotor areas using functional near infrared spectroscopy (fNIRS) and motor recovery within three months after a stroke. METHOD: Eight right-handed first ischemic/hemorrhagic stroke patients (60±8 years, 3 women) with mild to severe hemiparesis were examined with repetitive fNIRS measurements and motor recovery tests (Fugl-Meyer score) during two months. Hemodynamic changes over the ipsilesional and contralesional sensorimotor areas were collected from a multi-channel fNIRS system during intermittent isometric muscle contractions...
CONCLUSIONS: In this pilot study, repeated sessions of bi-hemispheric tDCS coupled with resistance training were found safe and tolerable for individuals at the chronic phase post-stroke. However, the use of tDCS did not result in additional sensorimotor improvements when compared to sham-tDCS. Further research is needed to better assess the clinical benefits of combining non-invasive transcranial stimulation with rehabilitation after a stroke. PMID: 31227673 [PubMed - as supplied by publisher]
CONCLUSIONS: Our study revealed that infusion of muscimol into the contralateral motor cortex during the repair stage could partially improve the behavioral performances without promoting axonal growth from uninjured hemisphere motor cortex to the denervated striatum and spinal cord, nor did it prevent the expression of axonal growth inhibitors in peri-lesioned cortex. More detailed studies will be required to clarify the role of GABAA Rs in regulating the behavioral recovery after a stroke. PMID: 31227671 [PubMed - as supplied by publisher]
If you or someone close to you have an autoimmune condition such as rheumatoid arthritis, lupus, Hashimoto’s thyroiditis, Crohn’s disease or ulcerative colitis, along with about 195 others, there are a number of steps you can take that reduce, even eliminate the autoimmune inflammation damaging your organs. (Unfortunately, some forms of autoimmune damage cannot be reversed. Autoimmune loss of pancreatic beta cells that lead to type 1 diabetes, Hashimoto’s thyroiditis that damages the thyroid gland, or autoimmune hepatitis that can lead to cirrhosis. for example, cannot be reversed even if the autoimmune p...
Conclusion In patients with advanced non-squamous NSCLC, the feasible dose of apatinib given with standard-dose pemetrexed and carboplatin was 500 mg/day schedule 2/1. The schedule was generally well tolerated and demonstrated promising clinical benefit in NSCLC.
Conclusion GX showed promising efficacy in patients with SRCC. GX could be considered as a treatment option for patients with SRCC and should be confirmed in larger clinical trials.